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Comparison of mitotic cell death by chromosome
fragmentation to premature chromosome
condensation
Joshua B Stevens1, Batoul Y Abdallah1, Sarah M Regan1, Guo Liu1, Steven W Bremer1, Christine J Ye1,
Henry H Heng1,2,3*
Abstract
Mitotic cell death is an important form of cell death, particularly in cancer. Chromosome fragmentation is a major
form of mitotic cell death which is identifiable during common cytogenetic analysis by its unique phenotype of
progressively degraded chromosomes. This morphology however, can appear similar to the morphology of
premature chromosome condensation (PCC) and thus, PCC has been at times confused with chromosome
fragmentation. In this analysis the phenomena of chromosome fragmentation and PCC are reviewed and their
similarities and differences are discussed in order to facilitate differentiation of the similar morphologies. Further-
more, chromosome pulverization, which has been used almost synonymously with PCC, is re-examined. Interest-
ingly, many past reports of chromosome pulverization are identified here as chromosome fragmentation and not
PCC. These reports describe broad ranging mechanisms of pulverization induction and agree with recent evidence
showing chromosome fragmentation is a cellular response to stress. Finally, biological aspects of chromosome
fragmentation are discussed, including its application as one form of non-clonal chromosome aberration (NCCA),
the driving force of cancer evolution.
Introduction
Morphological characterization of abnormal chromo-
somes represents an important aspect of medical genet-
ics. Modern medical genetics was firmly established
following the successful identification of trisomy 21 in
Down syndrome [1]. Since then other types of chromo-
some aberrations have been identified and linked to var-
ious diseases including cancer [2]. Diverse abnormal
chromosomal structures have been detected including;
translocations, duplications, deletions, inversions, fusion,
double minute chromosomes, chromosomal breaks, sis-
ter chromatid exchange (SCE), apoptotic bodies, and
defective mitotic figures [3,4], but shared chromosomal
aberrations have received the most attention [5,6]. Iden-
tification of recurrent chromosomal markers in patients
has greatly contributed to both diagnosis and patient
management, particularly in certain types of blood can-
cers with dominant recurrent changes [7].
Despite decades of intensive effort, identification of
commonly shared chromosome aberrations for most
diseases has been difficult [4-9]. In contrast, large num-
bers of nonrecurring chromosome aberrations have
been observed but generally ignored based on the view-
point that these non-recurrent chromosomal aberrations
are insignificant genetic noise [5,6,9-11]. Increasing evi-
dence demonstrates that non-recurrent genetic change
including non clonal chromosome aberrations (NCCAs),
are the main contributing factor in diseases involving
system instability and specifically have been identified as
the driving force of cancer progression [5,6,8-11].
According to the recently established genome theory,
stochastic chromosome alteration plays a key role in
both organismal and in somatic cell evolution. Stochas-
tic genome alterations have also been closely associated
with a large number of diseases [12]. Thus, systematic
characterization of various types of NCCAs and their
application to clinical diagnosis is of importance.
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Chromosome fragmentation is one type of recently
identified NCCA that requires more attention [13].
Chromosome fragmentation is a non-apoptotic form of
mitotic cell death, and is observed from an array of cell
lines and patient tissues. Its occurrence is associated
with various drug treatment or pathological conditions.
New data also illustrates that it is a programmed cell
death as PARP is readily degraded during the process of
chromosome fragmentation, where chromosomal frag-
mentation occurs as a general response to cellular stress
including oxygen stress, ER stress and various pathologi-
cal stresses (Stevens et al submitted).
The identification of chromosome fragmentation as a
form of cell death is new to the field, but the morpholo-
gical description of chromosome fragmentation is not.
With similar morphologies, chromosome pulverization
and PCC have been extensively studied since the 1960s
[14,15]. Many studies have confused the identity of pul-
verization and PCC due to their similar morphologies.
In regards to reassessing the classification of chromoso-
mal abnormalities, the further analysis of chromosome
fragmentation, a form of mitotic cell death, has renewed
interest in phenomena such as chromosome shattering
and pulverization. The identification of chromosome
fragmentation as a distinct form of cell death shows that
the issue of PCC/pulverization/shattering also needs to
be reexamined to establish the relationship among dif-
ferent cytogenetic identities. In this review these often
confused processes are analyzed from both a morpholo-
gical and mechanistic aspect. Finally, the relationship
between chromosome fragmentation and genome sys-
tem dynamics is discussed in light of the genome theory.
Brief over views of chromosome fragmentation and PCC
Chromosome fragmentation
Chromosome fragmentation is a major form of mitotic
cell death that is identified through abnormal cytoge-
netic figures [4,13]. These figures contain chromosomes
with multiple breaks, similar to the morphology of
S-phase PCC which is discussed below. During the pro-
cess of chromosome fragmentation the number of chro-
mosomal breaks increases until all chromosomes are
completely degraded. They often show lighter density
Giemsa or DAPI staining than normal chromosomes
stained in parallel indicating the loss of chromosomal
material. Morphologically, chromosome fragmentation
can be grouped into at least three groups: early frag-
mentation where few chromosomes are broken; mid-
stage fragmentation where a significant number of the
chromosomes have been fragmented; and late stage frag-
mentation where all or most of the chromosomes have
been fragmented which suggests it is a progressive pro-
cess (Figure 1). This progressivity is illustrated by time
course experiments where more late stage chromosome
fragmentation is detectable with longer treatment [13].
Chromosome fragmentation is non-apoptotic as evi-
denced by differences in morphology and other bio-
chemical differences [13]. Apoptosis results in
cytogenetic figures typified by small round clusters of
spontaneously condensed (not mitotic condensation)
fragmented DNA [16]. Chromosome fragmentation is
further distinguished from apoptosis as it is not reliant
on caspase activity, nor is it affected by Bcl-2 over-
expression [13]. Mechanistically it occurs as a general
response to stress (Stevens et al. submitted). The stres-
ses that have been shown to induce chromosome frag-
mentation are diverse in nature ranging from
commonly used chemotherapeutics with various mole-
cular mechanisms, to the targeting of specific stress
pathways such as the unfolded protein response, to
changes in culture conditions including temperature
change and oxygen concentration, to genomic instabil-
ity, and to various pathologies including cancer. The
link between chromosome fragmentation and genomic
instability is significant as the cellular system is forced
to change in response to genome change, creating
stress within the cell. Chromosome fragmentation like
other forms of cell death, functions as a response to
said stress in order to maintain genome integrity.
Premature Chromosome Condensation (PCC)
PCC was first described in 1970 by Johnson and Rao,
using cellular fusion methods developed previously
[14,17]. PCC was shown to occur when two asynchro-
nous cells fuse if one of these cells was in mitosis. This
was originally carried out using the UV inactivated Sen-
dai virus [14]. Methods were subsequently developed to
induce fusion using chemicals such as polyethylene gly-
col [18]. More recent mitotic catastrophe work has uti-
lized cell lines transfected with the HIV envelope
protein and the CD4 receptor to induce fusion [19].
Aside from fusion based PCC, a second method of
induction has also been reported where chemical inhibi-
tors of the cyclin b/cdk1 inhibitor, protein phosphotase
C have been utilized, negating the need for cellular
fusion [15]. Inhibitors of protein phosphotase C include
okadaic acid and calyculin A [15,20,21]. Recent reports
have demonstrated the utility of calyculin A in cytoge-
netic analysis, particularly within tumors [15]. Tumors
are collections of asynchronously dividing cells, often
with a low mitotic index rendering cytogenetic analysis
difficult. Calyculin A allows for cytogenetic analysis of
tumor cells without culture as all G2/M cells can be
analyzed.
PCC results in three distinct chromosomal morpholo-
gies determined by the cell cycle progression of the
induced cell [22,23]. G2 PCC chromosomes are similar
in morphology to normal mitotic chromosomes with
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sister chromatid attachment and no breaks or gaps,
though chromatids are longer than metaphase chromo-
somes, similar to chromosomes in early prophase. G1
PCC is similar in appearance to G2 PCC, except there
are no sister chromatids as replication has not been
started. In S-phase PCC chromosomes appear as con-
densed pieces of chromatin or chromosomes with multi-
ple breaks and gaps, depending on how far replication
has proceeded [23]. The main focus of this review will
focus on S-phase PCC, as its morphology is often con-
fused with that of chromosome fragmentation.
Fusion and chemical inhibitor based methods of indu-
cing PCC are similar in molecular mechanism and mor-
phology. Both methods result in exposure of an
interphase cell to the activated cyclin b/cdk1 complex
(also known as mitosis promoting factor or MPF) [15].
In fusion PCC the activated complex is provided by the
mitotic cell, whereas in inhibitor induced PCC, the com-
plex is prematurely activated through inhibition of pro-
tein phosphatases that dephosphorylate cyclin b in order
to keep it inactive [15,24]. This difference results in two
small differences in morphology. The first is that in
fusion based PCC nuclei/chromosomes from the fused
cells are always in close proximity to each other [14,25].
The second difference between the two is that G1 PCC
rarely occurs in chemical inhibitor based PCC as little
or no cyclin b can be found in the cell until mainly S-
phase [15]. In the case of fusion PCC, G1 PCC is readily
detectable as the mitotic cell provides enough activated
cyclin b/cdk1 complex to drive condensation of unrepli-
cated G1 chromosomes.
PCC has applications in the research lab and the
clinic. Chemical induction of PCC can be used to
increase the number of mitotic cells within tumor
samples, allowing for rapid karyotyping with only very
short term culture being required [15]. PCC can also be
used in order to perform cytogenetic evaluation of
quiescent and senescent cells. This will likely gain in
importance as the measure of karyotypic diversity is
used on a more regular basis in cancer treatment and
monitoring [26]. In addition, PCC has been used in
making clinical predictions [27]. Elevated PCC can also
be detected in various disease conditions including can-
cer, microcephaly and mental retardation [28,29]. Chro-
mosome fragmentation has been often confused with
PCC, and we have recently illustrated that chromosome
fragments are frequently observed in various types of
experimental and pathological stresses including various
diseases. Therefore, an examination of whether these
previously observed PCCs are in fact chromosome frag-
mentation is now needed. One possibility is that the
process of inducing PCCs may also induce chromosome
fragmentation and PCCs may also be an indicator of
system stress. Clearly, further investigation is needed to
address these issues.
Chromosome pulverization/shattering
Multiple reports analyze two phenomena called chromo-
some pulverization or chromosome shattering [30-32].
These terms have been used synonymously with PCC or
in some cases have been associated with cell death.
A variety of mechanisms have been used to induce pul-
verization, frequently including viral infections or drug
treatments. A summary of these reports is found in
Table 1. Taken together, these reports all show highly
varied mechanisms of induction of pulverization, and
few offer clear-cut evidence that the given conditions
actually induce PCC. When considered in light of chro-
mosome fragmentation, this confusion can be resolved.
Figure 1 Examples of the various stages of chromosome fragmentation in a subclone of HCT116 human colon carcinoma cells. A. Early
stage chromosome fragmentation where most chromosomes are intact. Chromosomes being degraded are denoted by arrows. The degree of
condensation occurring in the chromosomes should be noted and are very condensed when compared to the small degree of condensation
occurring in the examples of S-phase PCC in figure 2. B. Mid-stage chromosome fragmentation where most chromosomes still display some
chromosomal morphology despite multiple breaks. Nearly complete chromosomes are also identifiable (arrowheads). C. Late stage chromosome
fragmentation where most chromosome morphology has been lost due to degradation despite the fragments still retaining a high degree of
condensation. A small number of chromosomes are nearly intact (arrowheads).
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The vastly ranging mechanisms of chromosome pulveri-
zation and/or shattering are all diverse stresses impact-
ing the cellular system. When that system is unable to
adapt to or recover from the stress, the cell must then
be eliminated. This is carried out through a number of
death processes including chromosome fragmentation
(Stevens et al, submitted). Thus chromosome pulveriza-
tion often has little to do with PCC but rather is chro-
mosome fragmentation.
Previous reports have shown chromosome fragmen-
tation but have called it chromosome pulverization/
shattering, therefore one option is to continue to use
the term(s) shattering/pulverization, however there are
a number reasons not to do so. They include the fol-
lowing: First, descriptions of pulverization have focused
largely on identification of later stage fragmentation
events. The term chromosome fragmentation encom-
passes all stages of this mitotic cell death while pulver-
ization has only been used to describe late stages.
Second, DNA fragmentation is used to describe the
genome degradation that takes place during apoptosis
[29]. Therefore, in keeping with the term fragmenta-
tion to denote cell death related genome breakdown,
the term chromosome fragmentation is used. The term
chromosome fragmentation has been used synony-
mously with pulverization in limited reports, thus
there is a historical basis for the use of the term chro-
mosome fragmentation [33]. Finally, chromosome pul-
verization has been used synonymously with PCC to
the extent that they have been inextricably linked.
Thus using the term chromosome fragmentation averts
any erroneous links.
Similarities and differences between chromosome
fragmentation and PCC
Chromosome fragmentation and PCC can be confus-
ingly similar, so what exactly differentiates these phe-
nomena? In the following discussion, chromosome
Table 1 Various stresses that have been linked to chromosome pulverization/shattering
Factors of pulverization/shattering Species Ref.
Shattering due to UV light and caffeine exposure Chinese Hamster [44]
Maintenance of diploid karyotype in PA-1 cells by removal of tetra ploid cells Human [62]
UV exposure Tradescantia
paludosa
[66]
Cells with herpes-like virus given doses of colcemid Human [67]
Exposed to various doses of tritiated thymidine Chinese Hamster [68]
Exposure of male mice to methyl methanesulfonate previous to fertilization of female mice. Shattering seen in filial cells Mouse [69]
Infection of lymphocytes with JM-V herpes-virus Chicken [70]
Treatment with fungicide N-trichloromethylthio-phthalimide Human [71]
Pulverization due to UV light and caffeine Chinese Hamster [72]
Exposure to alpha-amanitin Rat [73]
Doxorubicin treatment. Pulverization inhibited in drug resistant cells. Human [74]
Herpes simplex virus type 1 infection Human [75]
Hepatitis B infection. Pulverization occurs in both a hepatocellular cell line derived from a tumor and in peripheral
lymphocytes from the patient.
Human [76]
Herpes simplex virus type 1 infection. Endoreduplication was noted. Also HSV infection increased the mitotic index. Human [77]
Friend leukemia cells exposed to high levels of adriamycin. Mouse [78]
Following incubation of cells with heat labile DNA polymerase A in S phase at 39°C which were then cultured in a
permissive temperature.
Mouse [79]
Photo-irradiation of G2 or early prophase cells. CHO [80]
Hepatitis B integration and genomic instability Human [81]
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), sodium selenite and caffiene treatment of CHO cells Chinese Hamster [82]
Culture of a fibroblast line generated from a patient with xeroderma Human [83]
Associated with ubiquitin-activating enzyme E1 activity Mouse [84]
Vaccination against hog cholera virus Pig [85]
Radiaton exposure in bone marrow. Treatment with WR-2721 and/or Ocimum sanctum extract reduced the amount of
pulverization.
Mouse [86]
2-methoxyestradiol, an endogenous metabolite of estrogen Human [87]
Following vaccination of pigs for swine fever Pig [88]
Streptozotocin treatment Human [89]
Viral infection in pigs Pig [90]
Vitamin C treatment of lymphocytes Human [91]
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fragmentation and PCC will be differentiated first by
morphology and then by mechanism (Table 2).
Morphology
S-phase PCC and chromosome fragmentation each
produce striking mitotic figures where gaps/breaks are
interspersed among pieces of condensed chromosomes
[13,14,34]. Subtleties that differ between each can be
useful in distinguishing chromosome fragmentation
from PCC. An easy way to identify fusion based PCC
is through close association of a normal mitotic cell
with the cell undergoing S-phase PCC. Well-controlled
cytogenetic preparation with restrained hypotonic
treatment used to make chromosome spreads often
does not result in a broken membrane, so cells that
have fused membranes will retain their close associa-
tion when cytogenetic slides are prepared. Careful slide
preparation, where samples are diluted enough so that
resulting cell suspension drops do not land too close
to one another, but not so much so that there is insuf-
ficient material to analyze, is key to ensuring chromo-
some fragmentation is not considered PCC. Although
fusion based PCC is the easiest form of PCC to distin-
guish from chromosome fragmentation, chemical
induced PCC can also be distinguished based on
morphology.
Most mitotic figures from cells undergoing chromo-
some fragmentation show variable degrees of fragmenta-
tion across the chromosomes where chromosomes that
are completely degraded are found within figures that
also contain completely intact chromosomes and every
degree of degradation between these extremes also can
be seen (Figure 1). In human cells, PCC figures have less
variability as replication takes place relatively similarly
across the entire complement of chromosomes. There
are, however, limited examples of single chromosome
pulverization in highly heterochromatinized chromo-
somes that undergo delayed replication [35]. Also, multi-
nucleated cells can undergo asynchronous replication
leading to PCC in a limited number of chromosomes and
this is discussed in the following paragraph [36]. In cases
of early stage chromosome fragmentation there may be
only one or a handful of chromosomes that are fragmen-
ted. This does not typically occur during PCC as the pro-
gression of replication is relatively consistent across all
chromosomes. Chromosome fragmentation is often
induced in the presence of microtubule dynamics inhibi-
tors such as colcemid or docetaxel. This treatment can
result in overly condensed chromosomes, and chromo-
some fragmentation is often detectable in spreads with
highly condensed chromosomes. Chromosomes that are
prematurely condensed do not over-condense and in fact
are typically under condensed. This distinction offers yet
one more way to discriminate chromosome fragmenta-
tion and PCC. Furthermore, electron microscopy of PCC
shows that the areas in S-phase PCC figures that appear
to be gaps are not actually broken, but rather are single
strand DNA that has not yet been replicated [37]. Strand
breaks are detectable in the case of chromosome frag-
mentation by g-H2AX staining and not in the case of
PCC [13]. We thus anticipate that electron microscopy of
chromosome fragmentation will show strand breaks
between fragments.
Multinucleated and micronucleated cells are an inter-
esting case where chromosome fragmentation and PCC
can occur and affect a limited amount of the genome
within the multinucleated cell. Multinucleated cells are a
common occurrence in tumors, indicative of genomic
instability, not commonly shared and are therefore one
type of NCCA [38,39]. In multinucleated cells, although
each nuclei is located within the same cell, each nuclei
can replicate at different times [36]. The differential repli-
cation can result in entrance into mitosis in one nuclei
while another may still be in S-phase. Mitotic entry of
one nuclei causes exposure of the other nuclei to MPF
driving it into premature mitosis [36]. This occurs in
under 50% of multinucleated cells with apparent
Table 2 Identifiable differences of chromosome fragmentation and PCC
Chromosome fragmentation PCC
Morphologic
Single cell involvement If fusion induced, normal, intact mitotic cells will be in close proximity to fragmented cells
Can affect single chromosomes Impacts entire genome regularly, except in limited multinucleated cells
Results in chromosome degradation Unknown, may activate chromosome breakdown
Chromosome morphology lost as process progresses Chromosome morphology dependant on position in cell cycle
Differential cut size Differential condensation states
Mechanistic
Occurs during mitosis Occurs in interphase cells exposed to active MPF
Not inhibited by roscovitine Inhibited by roscovitine
Induced by stress during mitosis Induced by cell fusion or activation of MPF
g-H2AX positive g-H2AX negative
No active DNA incorporation Actively incorporating DNA
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pulverization, thus it is more common for multinucleated
cells to eliminate extraneous nuclei through chromosome
fragmentation than for that material to undergo PCC
[36]. One method of determining whether a micronu-
cleus is undergoing PCC is through detection of DNA
incorporation, morphological assessment of cells can also
indicate multinucleate associated PCC may be inducing
single chromosome fragmentation. First, for single or few
cell chromosome fragmentation to be PCC cells must be
multinucleated and multinucleated cells should be appar-
ent within the observed population. Second, within the
chromosome spread it is unusual for a pulverized micro-
nucleus to be surrounded by intact chromosomes. If a
fragmented chromosome is completely surrounded by
intact chromosomes the fragmented chromosome is unli-
kely to be derived from a different nucleus undergoing
PCC. Lastly, chromosome fragmentation and PCC are
distinguishable by g-H2AX staining. If the pulverized
chromosome(s) in question is not positive for g-H2AX, it
is likely PCC, whereas if it is, it is being degraded by
chromosome fragmentation.
It should be pointed out that chromosome fragmenta-
tion is a unique phenomenon of mitotic cell death, and
should not be confused with just any type of chromoso-
mal breakage. Chromosome fragmentation involves
chromosome breaks, but this does not mean they are
the same. For example, the recently reported phenom-
enon that there appears to be chromatin tethers that
hold broken chromosomes together is likely not asso-
ciated with chromosome fragmentation [40]. It would be
difficult to imagine that the massive fragmentation that
occurs during chromosome fragmentation could be res-
cued by this tether mechanism, as studies have clearly
linked chromosome fragmentation to mitotic cell death
[13]. It is likely that only a very limited number of
breaks could be overcome in a few generations by this
tether mechanism.
Mechanism
Further work has also separated the two distinct phe-
nomena. Chromosome fragmentation was not inducible
in double thymidine blocked S-phase cells that remained
in interphase (Stevens unpublished observation). This
indicates that these cells arrested properly in either
S-phase and/or G2 and were not able to prematurely
enter mitosis. PCC, when the morphology is similar to
chromosome fragmentation, occurs specifically in cells
in S-phase [15]. Interspersed segments of replicated and
unreplicated DNA manifest as condensed DNA with
intervening empty spaces similar in morphology to
chromosome fragmentation (Figure 2). If chromosome
fragmentation occurs in mitosis, there should be no
DNA incorporation, whereas if it is related to S-phase
DNA replication it should be detectable. DNA synthesis
can be directly monitored by the inclusion of the thymi-
dine analog, bromo-deoxyuridine (BrdUrd). In mitotic
arrested cells induced to undergo chromosome fragmen-
tation no BrdUrd incorporation was shown, however
BrdUrd was detectable in asynchronous cells induced to
undergo PCC by calyculin A [13]. This suggests that,
despite the morphological similarity between chromo-
some fragmentation and PCC, they are in fact distinct
processes.
Figure 2 Examples of S-phase PCC induced by 80 nM calyculin A treatment. Later S-phase PCC (A.) and earlier S-phase PCC (B.) are
shown. In later S-phase PCC chromosomes are nearly completely replicated and have fewer gaps than early S-phase PCC. In both stages
chromosomes are not highly condensed.
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PCC results in the abnormal activation of MPF, so inhi-
bition of this activation would inhibit PCC. Roscovitine is
a purine analog that functions as an inhibitor of the G2 to
M transition through inhibition of CDK1 activity [41,42].
Roscovitine treatment should inhibit PCC, but not any
mitotic processes, as cells that are already in mitosis are
not inhibited by treatment. Mitotic cells treated with ros-
covitine and 1 ug/ml doxorubicin concurrently while still
under colcemid pressure readily undergo chromosome
fragmentation (Stevens et al. Submitted). This further sup-
ports the conclusion that chromosome fragmentation and
premature chromosome condensation are not the same
process. Thus chromosome fragmentation and S-phase
PCC can be distinguished based on both morphological
and mechanistic assessment.
Chromosome fragmentation, PCC and the G2 checkpoint
Though chromosome fragmentation and PCC can typi-
cally be differentiated based on morphological and
mechanistic differences there is potential overlap of the
two. This potential overlap occurs at the G2 checkpoint
where any potential DNA damage is repaired prior to
mitosis. Induction of PCC occurs through the abnormal
activity of MPF subsequently subverting the G2 check-
point. Traditionally, caffeine has been used to inhibit the
G2 checkpoint and concurrent treatment with various
drugs or radiation can result in chromosome fragmenta-
tion [30,43-45]. UCN-01, is a recently developed che-
motherapeutic that reduces the ability of cells to arrest in
G2 [46]. It has shown great promise in in vitro studies
and is now in active clinical trials [47-49]. Concurrent
treatment with UCN-01 and other drugs such as topoi-
somerase inhibitors potentiates cell death to a synergistic
level [50]. Chromosome fragmentation is induced
strongly in doxorubicin and UCN-01 treated cells. On
one hand, these cells are prematurely entering mitosis in
that they should arrest at the G2 checkpoint, but because
the checkpoint is inhibited these damaged cells enter
mitosis. On the other hand, these cells have completed
S-phase and do not contain the large blocks of un-
replicated DNA that typifies S-phase PCC cells. Differen-
tiation of the two phenomena comes from PCC resulting
from the artificial activation of MPF. In this case MPF is
activated at the normal time; however inhibitory signals
of the G2 checkpoint are unable to slow the process.
Cells then enter mitosis with irreparable damage and are
eliminated through the degradative process of chromo-
some fragmentation. Similarly, the same process can hap-
pen when cells lacking G2 checkpoint activity have
replication inhibited by treatment with aphidicolin [51].
In this system ATR null cells are unable to arrest follow-
ing incomplete replication due to aphidicolin treatment
leading to premature entry into mitosis of cells with
under-replicated DNA. Again, the key to differentiating
chromosome fragmentation and PCC here is that follow-
ing mitotic entry, chromosomes undergo degradation. It
is not known if this degradation occurs in the cellular
fusion or chemical induced forms of PCC. Further work
is needed to determine if this happens or not.
Chromosome fragmentation and mitotic catastrophe
Mitotic catastrophe is often used to refer to mitotic
related cell deaths. However there is no distinct defini-
tion of this type of cell death. Reports vary widely and
include deaths that occur directly during mitosis, or
occur following a failed mitosis [52-56]. Due to the
ambiguity of the term mitotic catastrophe, its use has
been cautioned against [57], but because of the perva-
siveness of mitotic catastrophe within the literature and
its potential connections to chromosome fragmentation
and PCC, it will be briefly discussed.
Certain models of mitotic catastrophe, particularly
those that are based on cell fusion, are in fact suggestive
of PCC. However others are based on loose G2 check-
points [50,51]. When HCT116 cells are treated with
UCN-01 and doxorubicin, chromosome fragmentation is
detectable. This suggests that cells entering mitosis with
high enough levels of damage undergo chromosome
fragmentation. Cells with damage below this level may
undergo mitotic catastrophe and die in the subsequent
G1 phase through apoptotic mechanisms. However,
under normal conditions these cells should arrest and
not enter mitosis, and are in a sense undergoing PCC.
This PCC is different from classical S-phase PCC in that
this occurs after the DNA has been replicated in S-
phase, and in that it is not driven through forced MPF
exposure, either through fusion with mitotic cells or
activation caused by chemical inhibition. In fact, in
HCT116 cells treated with UCN-01, but without doxor-
ubicin, no increase in chromosome fragmentation is
detectable even though it is likely that some cells enter
mitosis through a G2 block over-ride. Early studies
describe what was believed to be S-phase PCC following
viral infection [58]. It was assumed that this phenom-
enon was the same as S-phase PCC induced through
cellular fusion because of the similarities in morphology.
It was hypothesized that this phenomenon was a
response by the infected cells to eliminate the viral
infection through self destruction [34]. It is possible that
some of the observations were actually of chromosome
fragmentation, which was induced because of genome
change and/or stress induced from the viral load, and
that these cells were responding in a protective manner.
Chromosome fragmentation is a non-clonal chromosome
aberration
Following the discussion of the importance of chromo-
some fragmentation in cell death, it is necessary to
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mention its importance in genome research as well as
future diagnostic use. Importantly chromosome frag-
mentation is one manifestation of the previously ignored
non-clonal chromosome aberrations. NCCAs reflect the
level of genomic instability within a population of cells,
which according to the principles of the genome theory,
are the driving force of cancer evolution and drug resis-
tance [4-6,8-12,59,60]. Chromosome fragmentation has
been shown to occur in response to genomic instability
serving to eliminate that instability and to protect the
cellular bio-system. System instability can be induced
through a number of cellular stresses, including single
gene change. It is important to note that association
between chromosome fragmentation and specific gene
change is often context dependant. In the case of p53,
p53 function itself was shown not to affect the induction
of chromosome fragmentation with doxorubicin [61]. In
another case however, when the functional status of p53
is changed, spontaneous levels of chromosome fragmen-
tation also change. When the status of p53 is changed
from non-functional to functional, there is a transient
die off of cells through both chromosome fragmentation
and apoptosis as stability is attained within that system
[13]. This is what happens in the H1299v138 system
where cells with a temperature sensitive p53 mutation
grow well at the restrictive temperature where p53 does
not function. Upon temperature shift and re-establish-
ment of p53 function, cells die via chromosome frag-
mentation and apoptosis until the population of cells
has adapted to the new system that incorporates p53
function [13]. In the MAD041 in vitro model of sponta-
neous transformation, p53 function is abrogated in the
germ line [12]. During transformation in this model,
stochastic chromosome instability increases until cells
reach crisis and a dominant clone is selected between
passage 20 and 30. Throughout this progression, chro-
mosome fragmentation increases and decreases in accor-
dance with genomic instability measured by non-clonal
chromosome aberrations. Taken together, this data indi-
cates that chromosome fragmentation reflects system
dynamics as well as playing an important role in elimi-
nating unstable cells in general.
Increased chromosome fragmentation has also been
shown to occur in the PA-1 cell line where chromosome
fragmentation takes place in order to eliminate poly-
ploidy cells [62]. Chromosome fragmentation can also
influence system dynamics not just by eliminating cells,
but also by altering the genomes of surviving cells. This
happens in two ways. First one or a small number of
chromosomes can be selectively degraded during the
chromosome fragmentation process leading to changes
in chromosome number. More drastic change can also
occur when the process does not complete. Incomplete
chromosome fragmentation can result in reattachment
of chromosomal fragments resulting in the creation of
very complex chromosomes with multiple translocations
also known as karyotypic chaos. Apoptotic cell death
can also lead to system change through horizontal trans-
fer, as DNA from apoptotic cells is taken up and incor-
porated by neighboring cells [63]. Whether chromosome
fragmentation can result in horizontal transfer remains
unknown. Further work is needed to address this issue.
What is clear however, is that chromosome fragmenta-
tion can not only change cellular systems by elimination
of selected cells, but chromosome fragmentation can
also result in changed karyotypes. The karyotype defines
the cellular system in both somatic cell evolution and
organismal evolution [64,65]. Therefore, chromosome
fragmentation can influence the creation of new cellular
systems which can lead to cancer and other diseases.
Although chromosome fragmentation is important to
maintain system stability, there are many redundant sys-
tems within cells that ensure that cells maintain home-
ostasis and are not permanently damaged at the genome
level. Chromosome fragmentation becomes activated
when cells reach mitosis with extensive damage or in
the face of extensive stress. Chromosome fragmentation
works in conjunction with other regulators of cellular
integrity, such as the cell cycle checkpoints and other
forms of programmed cell death (apoptosis and autop-
hagy), to maintain the cellular system identity. There-
fore, chromosome fragmentation can be applied as a
clinically useful measure of NCCAs. Furthermore, chro-
mosome fragmentation frequencies have also been
shown to roughly approximate total NCCA levels. This
is significant, as chromosome fragmentation analysis can
be used as a relatively quick and inexpensive substitute
for spectral karyotyping in patient monitoring. Although
chromosome fragmentation indices may not hold all the
information that SKY analysis could reveal, it does give
an overall estimate of the genomic instability contained
within a given sample. This information combined with
information from the same slides such as mitotic index,
frequency of apoptotic cells, and frequency of micronu-
clei may be useful in determining treatment modalities
in many diseases including cancer.
Conclusion
Chromosome fragmentation is a form of mitotic cell
death that was only recently characterized. In some
manifestations, chromosome fragmentation can appear
quite similar to PCC. However in depth analysis shows
that chromosome fragmentation and PCC are in fact
quite different phenomena, though at times they may be
linked to each other. They are distinguishable by mor-
phological and mechanistic analyses. Distinguishing
between chromosome fragmentation and PCCs is signif-
icant. Demonstration that they are two independent
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biological phenomena means that chromosome frag-
mentation can now be used as an easily applied cytoge-
netic index to measure mitotic cell death that could
have clinical and basic research applications. In addition,
despite decades of extensive studies, there is little known
about the biological significance of chromosome pulveri-
zation. By separating chromosome pulverization from
PCC, a long standing puzzle can now be solved. It now
seems that the biological meaning of PCCs is rather lim-
ited. Well controlled experiments are needed to further
separate PCC and chromosome fragmentation. In addi-
tion, chromosome fragmentation has been identified as
a form of NCCA, which is the driving force of cancer
progression, and therefore analyses of chromosome frag-
mentation in clinical settings could lead to better treat-
ments and outcomes in cancer therapy.
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